Nonalcoholic Fatty Liver Disease Plasma

Nonalcoholic Fatty Liver Disease Plasma for Metabolic Liver Disease Research

Nonalcoholic Fatty Liver Disease Plasma is collected from IRB-consented donors clinically diagnosed with nonalcoholic fatty liver disease (NAFLD) and processed within one day of collection to preserve cytokines, proteins, lipids and metabolites. Plasma is acellular, so this product is intended for soluble-analyte measurement rather than cell-based assays.

NAFLD Metabolic Biology and Why Plasma

NAFLD is a metabolic liver disease. It is not autoimmune. The disease begins with excess triglyceride accumulation in hepatocytes and is tightly coupled to insulin resistance and adipose tissue dysfunction.

  • Hepatic steatosis develops when fatty acid delivery and de novo lipogenesis exceed oxidation and export, driven in large part by peripheral and hepatic insulin resistance
  • Lipotoxicity from specific lipid species, rather than triglyceride storage alone, is thought to drive hepatocyte stress, injury and cell death
  • A subset of donors progress from simple steatosis to steatohepatitis, with hepatocyte ballooning, lobular inflammation and metabolic inflammation involving resident and recruited immune cells
  • Ongoing injury activates hepatic stellate cells, producing progressive fibrosis that can advance to cirrhosis and is the strongest predictor of clinical outcome
  • Plasma carries the analytes used to track all of this non-invasively: aminotransferases, adipokines, insulin and glucose for HOMA-IR calculation, lipid species, and extracellular matrix turnover markers
  • Plasma is the correct matrix for the non-invasive fibrosis panels and multi-analyte scores that are widely used in place of repeat biopsy

Donor Stratification Available

  • Simple steatosis versus nonalcoholic steatohepatitis where histologically or clinically characterised
  • Fibrosis stage or non-invasive fibrosis score where available
  • Presence or absence of comorbid type 2 diabetes
  • BMI and obesity class
  • Method of diagnosis: imaging, elastography, or liver biopsy
  • Comorbid dyslipidaemia, hypertension, or metabolic syndrome
  • Matched healthy controls available

Product Features

  • Research Use Only (RUO)
  • Plasma collected from clinically confirmed Nonalcoholic Fatty Liver Disease donors
  • Processed within one day of collection
  • IRB-approved protocols and informed consent
  • Custom aliquot volumes available upon request
  • Anticoagulant selection available on request to match your assay

De-identified Donor Data

  • Verified Nonalcoholic Fatty Liver Disease diagnosis
  • Demographic data: age, sex assigned at birth, race/ethnicity, BMI
  • Donor-reported medications, allergies, and comorbidities
  • Liver function test results where available
  • Additional nonalcoholic fatty liver disease-specific metadata available

Applications

  • Non-invasive fibrosis biomarker discovery and validation
  • Insulin resistance and adipokine profiling
  • Plasma lipidomics and untargeted metabolomics
  • Extracellular matrix turnover marker measurement
  • Metabolic inflammation cytokine profiling
  • Plasma proteomics for steatohepatitis versus simple steatosis discrimination
  • Diagnostic assay and multi-analyte panel development
  • Therapeutic response research for metabolic liver disease candidates

Other Nonalcoholic Fatty Liver Disease Specimen Types

Compliance and Quality Assurance

  • IRB-approved and HIPAA-compliant protocols
  • Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
  • Documentation support available for regulatory review

Ordering & Customization

Nonalcoholic Fatty Liver Disease plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse plasma from other disease states and check live stock status, visit our human plasma page.

Protocols & Documentation

  • Plasma Isolation

    Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Plasma

Frequently Asked Questions

Showing 1–12 of 31 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom Plasma cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information